Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 28 peer-reviewed journal articles Updated
Oncology

Treatment Strategies for Adults: Standard of Care

At a Glance

The standard of care for adult Anaplastic Large Cell Lymphoma (ALCL) depends on the specific subtype. Systemic ALCL is typically treated with targeted BV-CHP therapy, while Breast Implant-Associated ALCL (BIA-ALCL) is often cured with specialized surgery to remove the implant and capsule.

In recent years, the treatment landscape for adult Anaplastic Large Cell Lymphoma (ALCL) has undergone a major shift. We have moved from using general chemotherapy to “targeted” strategies that are more effective at clearing the cancer [1][2]. Your treatment path depends entirely on the subtype of ALCL you have and how far it has spread.

A Note on Fertility Preservation

Before starting systemic treatments like chemotherapy, it is critical to ask your doctor about fertility preservation options (like egg or sperm freezing). Because these treatments can impact future fertility, addressing this before therapy begins is a standard of care.

The New Standard: Systemic ALCL

For decades, a chemotherapy blend called CHOP was the go-to treatment. However, a major study called the ECHELON-2 trial changed the standard of care for adults [3][4].

The trial showed that replacing the drug vincristine (the “O” in CHOP) with brentuximab vedotin (BV) created a superior regimen known as BV-CHP [1][5]. Vincristine was specifically removed because combining it with BV causes severe, overlapping peripheral neuropathy [3].

  • The Result: Patients receiving BV-CHP lived longer and stayed in remission longer than those on the old CHOP therapy [3][6].
  • How it Works: BV is an antibody-drug conjugate. It acts like a guided missile that finds the CD30 marker on the cancer cells and delivers a potent dose of medicine directly into them, sparing more of your healthy cells [7][5].

Treating BIA-ALCL: Surgery First

If you have Breast Implant-Associated ALCL (BIA-ALCL), the primary treatment is usually surgical rather than chemical [8].

  • En Bloc Resection: The “gold standard” is a surgery that removes the breast implant and the entire surrounding scar tissue (the capsule) in one piece [9][10]. Furthermore, standard guidelines strongly recommend removing the unaffected opposite (contralateral) implant and capsule at the same time to prevent future complications or hidden disease.
  • Curative Intent: For many patients whose cancer is confined to the fluid or the capsule, this surgery alone is enough to be considered a cure [11][12].
  • Adjuvant Therapy: If the cancer has spread into the breast tissue or lymph nodes, doctors may then add chemotherapy (like BV-CHP) or radiation [8][13].

Treating Primary Cutaneous ALCL (pcALCL)

If you have the skin-only version of ALCL, your treatment will likely be much less intensive than systemic chemotherapy [14].

  • Local Treatment: Often, pcALCL is treated simply with surgical excision of the skin lesions or local radiation therapy [15].
  • Systemic Therapy: Systemic treatments are usually only considered if the disease is widespread across the skin or moves into the lymph nodes [14].

Navigating Relapsed or Refractory Disease

If the lymphoma does not respond to the first treatment (refractory) or comes back later (relapsed), there are still several powerful lines of defense [16].

1. ALK Inhibitors (for ALK+ cases)

For patients with the ALK-positive subtype, drugs like crizotinib or alectinib can be highly effective [17][18]. These are often taken as pills and work by blocking the specific “broken switch” (the ALK protein) that fuels the cancer’s growth [19][20].

2. Stem Cell Transplantation

If a second remission is achieved using “salvage” therapy (a medical term simply meaning “second-line treatment” designed to get the cancer back into remission), your doctor may recommend a stem cell transplant to “reset” your immune system and prevent another relapse [21][22].

  • Autologous (ASCT): Uses your own collected stem cells [23].
  • Allogeneic (Allo-SCT): Uses stem cells from a donor and is typically reserved for more difficult cases [24][22].

3. Emerging Options: CAR-T Therapy

CAR-T cell therapy is a revolutionary new treatment where your own T-cells are genetically engineered in a lab to hunt down CD30-positive lymphoma cells [25][26]. While still primarily in clinical trials or reserved for specific cases, it has shown the ability to create long-lasting remissions in patients who had few other options [27][28].

Return to Home

Common questions in this guide

What is the standard chemotherapy for systemic ALCL?
The standard of care for adults with systemic ALCL is a targeted therapy regimen called BV-CHP. This combination uses brentuximab vedotin instead of vincristine to improve outcomes and reduce severe nerve damage compared to older treatments.
How is breast implant-associated ALCL (BIA-ALCL) treated?
The primary treatment is an en bloc resection, which is a surgery that removes the breast implant and the entire surrounding scar tissue capsule in one piece. For many patients whose cancer is confined to this area, this surgery alone is considered a cure.
What are the treatment options if ALCL comes back after remission?
If ALCL does not respond to initial treatment or comes back, doctors may use targeted ALK inhibitor pills for ALK-positive cases. Other powerful options include stem cell transplants to reset the immune system or emerging CAR-T cell therapies.
Should I discuss fertility options before starting ALCL treatment?
Yes, systemic treatments like chemotherapy can impact your future ability to have children. It is a standard part of care to discuss fertility preservation options, such as egg or sperm freezing, with your doctor before starting therapy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my ALCL diagnosis, will my frontline treatment be the BV-CHP regimen from the ECHELON-2 trial?
  2. 2.If we are considering surgery for BIA-ALCL, will it be an 'en bloc' total capsulectomy?
  3. 3.What is the goal of my initial treatment—is it curative or aimed at achieving remission for a transplant?
  4. 4.If my ALK-positive lymphoma returns, are ALK inhibitors like crizotinib or alectinib an option for me?
  5. 5.Am I a candidate for stem cell transplantation as a way to keep the cancer from coming back?
  6. 6.Are there fertility preservation options we should consider before starting chemotherapy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (28)
  1. 1

    Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.

    Nizamuddin I, Galvez C, Pro B

    Seminars in hematology 2021; (58(2)):85-94 doi:10.1053/j.seminhematol.2021.02.006.

    PMID: 33906726
  2. 2

    Frontline Management of Nodal Peripheral T-Cell Lymphomas.

    Ngu HS, Savage KJ

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2023; (43()):e390334 doi:10.1200/EDBK_390334.

    PMID: 37262395
  3. 3

    A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia

    Ma W, Zhao J, Zhang L

    Turkish journal of haematology : official journal of Turkish Society of Haematology 2021; (38(1)):87-89 doi:10.4274/tjh.galenos.2020.2020.0521.

    PMID: 33121225
  4. 4

    Recent advances and future perspectives in frontline treatment of peripheral T-cell lymphoma.

    Shirouchi Y, Yamauchi N, Maruyama D

    Japanese journal of clinical oncology 2026; (56(1)):24-32 doi:10.1093/jjco/hyaf158.

    PMID: 41066685
  5. 5

    BV and beyond: how to incorporate novel agents into PTCL management.

    Nizamuddin IA, Mehta-Shah N

    Hematology. American Society of Hematology. Education Program 2024; (2024(1)):54-61 doi:10.1182/hematology.2024000530.

    PMID: 39644004
  6. 6

    Updates in the Treatment of Peripheral T-Cell Lymphomas.

    Saleh K, Michot JM, Ribrag V

    Journal of experimental pharmacology 2021; (13()):577-591 doi:10.2147/JEP.S262344.

    PMID: 34188559
  7. 7

    Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy.

    Moskowitz AJ

    Hematology. American Society of Hematology. Education Program 2018; (2018(1)):207-212 doi:10.1182/asheducation-2018.1.207.

    PMID: 30504312
  8. 8

    Clinical recommendations for diagnosis and treatment according to current updated knowledge on BIA-ALCL.

    Longo B, Di Napoli A, Curigliano G, et al.

    Breast (Edinburgh, Scotland) 2022; (66()):332-341 doi:10.1016/j.breast.2022.11.009.

    PMID: 36502569
  9. 9

    Coming of Age: Breast Implant-Associated Anaplastic Large Cell Lymphoma After 18 Years of Investigation.

    Clemens MW, Miranda RN

    Clinics in plastic surgery 2015; (42(4)):605-13.

    PMID: 26408447
  10. 10

    Breast Implant-associated Anaplastic Large Cell Lymphoma Diagnosis 6 Years After Implant Removal: A Case Report.

    Barnea Y, Clemens MW, Madah E, et al.

    Annals of plastic surgery 2022; (88(2)):157-161 doi:10.1097/SAP.0000000000002945.

    PMID: 34270472
  11. 11

    Breast implant-associated anaplastic large cell lymphoma: a review.

    Quesada AE, Medeiros LJ, Clemens MW, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019; (32(2)):166-188 doi:10.1038/s41379-018-0134-3.

    PMID: 30206414
  12. 12

    A Prospective Approach to Inform and Treat 1340 Patients at Risk for BIA-ALCL.

    Roberts JM, Carr LW, Jones A, et al.

    Plastic and reconstructive surgery 2019; (144(1)):46-54 doi:10.1097/PRS.0000000000005703.

    PMID: 31246798
  13. 13

    Beyond surgery: the proper role and delivery of radiation therapy in the local-regional management of BIA-ALCL.

    Gunther JR, Iyer SP, Hunt KK, et al.

    Case reports in plastic surgery & hand surgery 2024; (11(1)):2389172 doi:10.1080/23320885.2024.2389172.

    PMID: 39119029
  14. 14

    No TP63 rearrangements in a selected group of primary cutaneous CD30+ lymphoproliferative disorders with aggressive clinical course.

    Schrader AM, Chung YY, Jansen PM, et al.

    Blood 2016; (128(1)):141-3 doi:10.1182/blood-2016-02-694455.

    PMID: 27146432
  15. 15

    Primary Cutaneous Anaplastic Large Cell Lymphoma with Locoregional Lymph Node Involvement: Challenges in Diagnosis and Clinical Management.

    Garcia-Garcia M, Tardin Cardoso AL, Val IS, et al.

    The American Journal of dermatopathology 2025; (47(11)):866-870 doi:10.1097/DAD.0000000000003103.

    PMID: 40810669
  16. 16

    ALCL: is it now a curable disease?

    Zinzani PL

    Blood 2017; (130(25)):2691-2692 doi:10.1182/blood-2017-10-811083.

    PMID: 29269528
  17. 17

    Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors: A case report.

    Saito S, Tashiro H, Sumiyoshi R, et al.

    Medicine 2021; (100(15)):e25576 doi:10.1097/MD.0000000000025576.

    PMID: 33847688
  18. 18

    Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK-Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan.

    Mori T, Kada A, Osumi T, et al.

    Cancer science 2026; (117(3)):777-786 doi:10.1111/cas.70308.

    PMID: 41457564
  19. 19

    Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin.

    Nakai R, Fukuhara S, Maeshima AM, et al.

    Clinical case reports 2019; (7(12)):2500-2504 doi:10.1002/ccr3.2543.

    PMID: 31893088
  20. 20

    Successful combination of crizotinib and hematopoietic stem cell transplantation in relapsed ALK-positive ALCL.

    Sun X, Fang X, Jiang Y

    Indian journal of cancer 2021; (58(1)):108-111 doi:10.4103/ijc.IJC_961_19.

    PMID: 33402581
  21. 21

    Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.

    Locatelli F, Mauz-Koerholz C, Neville K, et al.

    The Lancet. Haematology 2018; (5(10)):e450-e461 doi:10.1016/S2352-3026(18)30153-4.

    PMID: 30290902
  22. 22

    Management of Peripheral T-cell Lymphomas and the Role of Transplant.

    Foley NC, Mehta-Shah N

    Current oncology reports 2022; (24(11)):1489-1499 doi:10.1007/s11912-022-01310-3.

    PMID: 35947286
  23. 23

    Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma.

    Ishizawa K, Yanai T

    Advances in therapy 2019; (36(10)):2679-2696 doi:10.1007/s12325-019-01046-w.

    PMID: 31392578
  24. 24

    Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma: A Systematic Review and Meta-analysis.

    Du J, Yu D, Han X, et al.

    JAMA network open 2021; (4(5)):e219807 doi:10.1001/jamanetworkopen.2021.9807.

    PMID: 34042995
  25. 25

    CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas.

    Stein H, Falini B

    American journal of hematology 2026; (101(1)):110-128 doi:10.1002/ajh.70107.

    PMID: 41123243
  26. 26

    Emerging therapeutic strategies for CD30-positive lymphomas.

    Boretti A

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2026; (28(5)):1501-1515 doi:10.1007/s12094-025-04151-1.

    PMID: 41315095
  27. 27

    Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.

    Liu W, Wu J, Ming X, et al.

    Frontiers in immunology 2024; (15()):1346001 doi:10.3389/fimmu.2024.1346001.

    PMID: 38375471
  28. 28

    The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.

    Zhang S, Gu C, Huang L, et al.

    Scientific reports 2022; (12(1)):10488 doi:10.1038/s41598-022-14523-0.

    PMID: 35729339

This page provides educational information about standard treatments for adult ALCL. Always consult your oncologist to determine the most appropriate treatment plan for your specific diagnosis and subtype.

Get notified when new evidence is published on Anaplastic large cell lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.